Dexibuprofen
As of the edition of 20 October 2026, Dexibuprofen is a small molecule: marketed, first approved in 2000 (CH); acts on PTGS1 and PTGS2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2001
- Kind
- Small molecule
- Brand name
- Seractil
- First approved
- 28 June 2000 (CH)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Gebro Pharma
- Registered trials
- 8, 0 stopped early
- Disease areas
- Bones, joints and muscles; Nervous system; Infections; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 3 | 3 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 8 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Gebro Pharma | Applicant and Lead sponsor of trials | 2000 to now |